Kabir Nath, Chief Executive Officer, said, "During this past quarter, we commenced our COMP360 phase 3 pivotal program in treatment-resistant depression, a significant milestone for our area of science as these are the first ever phase 3 trials of psilocybin. We have also announced important updates to this program that accelerate the placebo-controlled trial pivotal data read out and streamline the long-term follow up as an integrated component of the pivotal trials. We are confident that this phase 3 program should generate the evidence to support a regulatory filing and to support broad patient access through integration into healthcare systems."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CMPS:
- COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlights
- COMPASS Pathways plc to announce fourth quarter and year-end 2022 financial results on 28 February 2023
- Rising High: Exclusive talk with funding solutions provider FundCanna
- Here’s What You Missed in Cannabis This Week
- Short Report: Bearish bets in crypto, EV technology recede amid profit-taking